PTX 9908

Drug Profile

PTX 9908

Alternative Names: PTX-9908

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pertinax Therapeutics
  • Class Antineoplastics; CXC chemokines; Peptides
  • Mechanism of Action CXCR4 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 26 Feb 2016 Phase-I/II development is ongoing in North America
  • 09 Sep 2013 Pertinax Therapeutics and MicroConstants China enter into a licensing and development agreement for Hepatocellular carcinoma in China
  • 09 Sep 2013 Phase-I/II clinical trials in Cancer (in healthy volunteers and patients) in North America (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top